The direct oral anticoagulants (DOACs), dabigatran, rivaroxaban, apixaban, and edoxaban,
are becoming the most commonly prescribed drugs for preventing ischemic stroke in …

Non-vitamin K antagonist oral anticoagulants (NOACs) are a therapeutic option to prevent
stroke in patients with atrial fibrillation (AF). In fact, NOACs have become the recommended …

Background and Aims A rising number of countries allow physicians to treat chronic pain
with medical cannabis. However, recreational cannabis use has been linked with …

Purpose Pharmacodynamic drug-drug interactions (PD DDIs) may influence the safety of
non-vitamin K antagonist oral anticoagulants (NOACs), but the extent to which PD DDIs …

Background/Aims There may be many predictors of anticoagulation-related gastrointestinal
bleeding (GIB), but until now, systematic reviews and assessments of the certainty of the …

Background Bleeding safety in relation to use of systemic fluconazole and topical azoles
among patients with atrial fibrillation treated with apixaban, rivaroxaban, or dabigatran is …

Background Non-vitamin K antagonist oral anticoagulants (NOACs) are currently the
mainstay treatment for preventing thrombosis-induced ischemic stroke in patients with atrial …

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is associated
with substantial increases in the risk for stroke and systemic thromboembolism. With the …

Background Limited knowledge of antihypertensive treatment of the elderly potentially
impedes effective strategies for hypertension management in this growing patient group. We …

Anticoagulation is common in patients undergoing routine musculoskeletal interventional
maneuvers. Previous retrospective studies have established the safety of continuing …